Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
6 hedge funds and large institutions have $15.3M invested in Hepion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
354% more capital invested
Capital invested by funds: $3.38M → $15.3M (+$12M)
100% more funds holding
Funds holding: 3 → 6 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$2.02M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.01M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$1.01M |
| 2 |
LWM
LBA Wealth Management
Jacksonville,
Florida
|
-$15K |
| 3 |
JFA
JNBA Financial Advisors
Bloomington,
Minnesota
|
-$1K |
| 4 |
S
SignatureFD
Atlanta,
Georgia
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Creative Planning
Overland Park,
Kansas
| $7K | – | – | – |
|
|
AIM
27
Acrospire Investment Management
Chicago,
Illinois
| $3K | – | – | – |
|
|
NFG
28
Next Financial Group
Houston,
Texas
| $2K | – | – | – |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
SBL
30
Sargent Bickham Lagudis
Boulder,
Colorado
| $1K | – | – | – |
|
|
VIA
31
Vantage Investment Advisors
State College,
Pennsylvania
| $1K | – | – | – |
|
|
JFA
32
JNBA Financial Advisors
Bloomington,
Minnesota
| – | -$1K | – | – |
|
|
LWM
33
LBA Wealth Management
Jacksonville,
Florida
| – | -$15K | – | – |
|
|
S
34
SignatureFD
Atlanta,
Georgia
| – | -$1K | – | – |
|
HEPA Hedge Fund Activity: Q4 2016 in Review
6 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2016, worth a combined $15.3M — up 354% from $3.38M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HEPA positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $2.02M. The largest seller was TIAA CREF Investment Management, cutting an estimated $1.01M.
- 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2016, up from 3 in Q3 2016.
- Funds reported $15.3M of Hepion Pharmaceuticals stock for Q4 2016, up 354% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q4 2016 and 0 closed out, a net change of +3 holders.
- The largest Hepion Pharmaceuticals buyer in Q4 2016 was HighTower Advisors, an estimated $2.02M added.
- The largest Hepion Pharmaceuticals seller in Q4 2016 was TIAA CREF Investment Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2016.